The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2
Open accessAbstract
Purpose: The ATP-binding cassette protein ABCG2 (breast cancer resistance protein) effluxes some of the photosensitizers used in photodynamic therapy (PDT) and, thus, may confer resistance to this treatment modality. Tyrosine kinase inhibitors (TKI) can block the function of ABCG2. Therefore, we tested the effects of the TKI imatinib mesylate (Gleevec) on photosensitizer accumulation and in vitro and in vivo PDT efficacy. Experimental Design: Energy-dependent photosensitizer efflux and imatinib mesylate's effects on intracellular accumulation of clinically used second- and first-generation photosensitizers were studied by flow cytometry in murine and human cells with and without ABCG2 expression. Effects of ABCG2 inhibition on PDT were examined in vitro using cell viability assays and in vivo measuring photosensitizer accumulation and time to regrowth in a RIF-1 tumor model. Results: Energy-dependent efflux of 2-(1-hexyloxethyl)-2-devinyl pyropheophorbide-a (HPPH, Photochlor), endogenous protoporphyrin IX (PpIX) synthesized from 5-aminolevulenic acid, and the benzoporphyrin derivative monoacid ring A (BPD-MA, Verteporfin) was shown in ABCG2+ cell lines, but the first-generation multimeric photosensitizer porfimer sodium (Photofrin) and a novel derivative of HPPH conjugated to galactose were minimally transported. Imatinib mesylate increased accumulation of HPPH, PpIX, and BPD-MA from 1.3- to 6-fold in ABCG2+ cells, but not in ABCG2− cells, and enhanced PDT efficacy both in vitro and in vivo. Conclusions: Second-generation clinical photosensitizers are transported out of cells by ABCG2, and this effect can be abrogated by coadministration of imatinib mesylate. By increasing intracellular photosensitizer levels in ABCG2+ tumors, imatinib mesylate or other ABCG2 transport inhibitors may enhance efficacy and selectivity of clinical PDT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Protein kinase inhibitors are suggested to potentially enhance the PDD efficacy by blocking ABCG2-mediated porphyrin efflux from cancer cells.”
In the citing paper
“Imatinib is the first kinase inhibitor shown to increase ALA-PpIX fluorescence and PDT in tumor cell lines through its interaction with ABCG2 [134].”
From 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy (2023) · cites this paper as [134]
Citations
Cites
1 retracted
RETRACTED: Stem cells in prostate and prostate cancer development
Lam, J. S., & Reiter, R. E. (2006) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.11.038 · Cited by 33
RetractedPhotodynamic therapy for cancer
Dolmans, D. E. J. G. J., Fukumura, D., & Jain, R. K. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1071 · Cited by 6,850
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Gomer, C. J. (1988) · Cited by 4,169
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plösch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202607599 · Cited by 822
Valk-Lingbeek, M. E., Bruggeman, S. W. M., & van Lohuizen, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.005 · Cited by 743
The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme
Krishnamurthy, P. C., Ross, D. D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K. E., Sarkadi, B., Sorrentino, B. P., & Schuetz, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313599200 · Cited by 668
Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System
Haraguchi, N., Utsunomiya, T., Inoue, H., Tanaka, F., Mimori, K., Barnard, G. F., & Mori, M. (2005) · Stem Cells · doi:10.1634/stemcells.2005-0282 · Cited by 577
Cited by
Sorted by citations
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Current states and future views in photodynamic therapy
Yano, S., Hirohara, S., Obata, M., Hagiya, Y., Ogura, S., Ikeda, A., Kataoka, H., Tanaka, M., & Joh, T. (2011) · Journal of Photochemistry and Photobiology C Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2011.06.001 · Cited by 545
Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies
Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 532
Robey, R. W., To, K. K. W., Polgár, O., Dohse, M., Fetsch, P. A., Dean, M. C., & Bates, S. E. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.003 · Cited by 473
The role of photodynamic therapy in overcoming cancer drug resistance
Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. G. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00495g · Cited by 341
Metadata
- Authors
- Liu, W., Baer, M. R., Bowman, M. J., Pera, P., Zheng, X., Morgan, J., Pandey, R. A., & Oseroff, A. R.
- Affiliations
- 1Dermatology, Departments of
- 2Medicine, and
- Roswell Park Comprehensive Cancer Center (US)
- Venue
- Clinical Cancer Research
- Published
- 2007-04-15
- Volume
- 13
- Issue
- 8
- Pages
- 2463-2470
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2147445587
- Cited by
- 136
- References
- 47
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 7 · 2017: 7 · 2016: 2 · 2015: 12 · 2014: 13 · 2013: 6 · 2012: 12
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cheng Kung University Hospital
- National Cancer Institute (P30 CA16056, P01 CA55791, P01CA055791, P30CA016056)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- imatinib mesylate, ABCG2, photodynamic therapy, photosensitizer accumulation, tyrosine kinase inhibitors, drug resistance, HPPH, protoporphyrin IX, verteporfin, porfimer sodium, combination therapy
- MeSH terms
- Imatinib Mesylate, ATP Binding Cassette Transporter, Subfamily G, Member 2, Antineoplastic Agents, Benzamides, Carcinoma, Squamous Cell, Combined Modality Therapy, Humans, Hypopharyngeal Neoplasms, Neoplasm Proteins, Photochemotherapy, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Photosensitizing Agents, ATP-Binding Cassette Transporters, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
